American Association for Cancer Research

sorry, we can't preview this file

21598290cd201661-sup-255535_2_supp_7025532_qqvy2y.docx (21.34 kB)

Supplementary Table 1 from IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity

Download (21.34 kB)
journal contribution
posted on 2023-04-03, 23:21 authored by Darya Alizadeh, Robyn A. Wong, Sharareh Gholamin, Madeleine Maker, Maryam Aftabizadeh, Xin Yang, Joseph R. Pecoraro, John D. Jeppson, Dongrui Wang, Brenda Aguilar, Renate Starr, Claire B. Larmonier, Nicolas Larmonier, Min-Hsuan Chen, Xiwei Wu, Antoni Ribas, Behnam Badie, Stephen J. Forman, Christine E. Brown

Supplementary Table 1


Mustang Bio. Inc.

California Institute for Regenerative Medicine

Cancer Center Support



Chimeric antigen receptor (CAR) T cells mediate potent antigen-specific antitumor activity; however, their indirect effects on the endogenous immune system are not well characterized. Remarkably, we demonstrate that CAR T-cell treatment of mouse syngeneic glioblastoma (GBM) activates intratumoral myeloid cells and induces endogenous T-cell memory responses coupled with feed-forward propagation of CAR T-cell responses. IFNγ production by CAR T cells and IFNγ responsiveness of host immune cells are critical for tumor immune landscape remodeling to promote a more activated and less suppressive tumor microenvironment. The clinical relevance of these observations is supported by studies showing that human IL13Rα2–CAR T cells activate patient-derived endogenous T cells and monocytes/macrophages through IFNγ signaling and induce the generation of tumor-specific T-cell responses in a responding patient with GBM. These studies establish that CAR T-cell therapy has the potential to shape the tumor microenvironment, creating a context permissible for eliciting endogenous antitumor immunity. Our findings highlight the critical role of IFNγ signaling for a productive CAR T-cell therapy in GBM. We establish that CAR T cells can activate resident myeloid populations and promote endogenous T-cell immunity, emphasizing the importance of host innate and adaptive immunity for CAR T-cell therapy of solid tumors.This article is highlighted in the In This Issue feature, p. 2113

Usage metrics

    Cancer Discovery



    Ref. manager